Decentralized Trials: Stakeholders Press FDA On Design Flexibility, Role Of HCPs, Harmonization

Dozens of stakeholders weigh in on FDA’s draft guidance for decentralized clinical trials. They question having a higher bar for DCTs, the new requirement for a task log, and the presumption data collected in these trials may be more variable than that from traditional trials.